Drug Trial Radar · NCT02682511
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Jan 2017
Primary completion
Mar 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Conditions
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Scleroderma, Limited
- Sclerosis, Progressive Systemic
- Skin Diseases
- Connective Tissue Diseases
- Pathologic Processes
- Autoimmune Diseases
Interventions
Oral IfetrobanDrug
Subjects will be treated with oral ifetroban or placebo daily for 365 days
Oral PlaceboDrug
Subjects will be treated with oral ifetroban or placebo daily for 365 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and Serious AEs (SAEs)Time frame: 56 weeks
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
The Universtity of Arizona Arthrtis Center
Tucson, Arizona
UCLA
Los Angeles, California
Cleveland Clinic - Florida
Weston, Florida
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Nebraska Medical Center
Omaha, Nebraska
Hospital for Special Surgery
New York, New York
Thomas Jefferson University
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Baylor Research Institute
Dallas, Texas
PGIMER
Chandigarh, Chandigarh, India
KDH - Kokilaben Dhirubhai Ambani Hospital
Mumbai, Maharashtra, India
B. J. Government Medical College
Pune, Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.